Genmab — Februar 2024
-
-
Genmab/JPMorgan: Estimaterne ligger for højt inden årsregnskab https://www.proinvestor.com/investornyt/1111231/genmab-jpmorgan-estimaterne-ligger-for-hojt-inden-arsregnskab
-
Lundbeck er ikke klar til at give op på CNS-kandidat
Lundbeck vil nu holde møder med myndighederne om, hvad det næste skridt på vejen kan være for CNS-kandidaten Lu AF82422. Et muligt pivotalt studie kan være på bordet. https://medwatch.dk/Medicinal___Biotek/article16808042.ece -
“The outcome of the trial is encouraging, despite not reaching statistical significance,” insisted Johan Luthman, head of R&D at the Denmark-headquartered group. “We will now finalise the analysis of the data and plan the next step for progressing the Lu AF82422 MSA programme in dialogue with health authorities,” he added. https://pharmaphorum.com/news/lundbeck-study-knocks-confidence-alpha-syn-cns-target
-
-
Godmorgen. Ny rekord i januar og ATH med 103.000 unikke besøgende på Proinvestor.com
-
Tak for indsatsen til alle jer skrivende brugere og til jer som læser med.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind